Scholarlink

Purpose of Review <p>Concerning the COVID-19 pandemic, repositioning several anticancer drugs has modulated SARS-CoV-2-induced inflammatory responses and disrupted viral replication. This review aims to discuss the potential of anticancer drug repositioning (DR) for anti-SARS-CoV-2 RdRp, its limitations, and other notable successes of DR against COVID-19.</p> Recent Findings <p>The emergence of SARS-CoV-2, an etiological agent that accounted for the current chaotic COVID-19 episode, has brought many lives away. Notably, the viral RNA-dependent RNA polymerase (RdRp) has contributed significantly to the viral replication of all RNA viruses, including SARS-CoV-2, making it a promising target for drug treatment. The lack of efficacious drugs combined with the prolonged duration of the drug discovery process has prompted many to opt for drug repositioning (DR) as an alternative route to combat current or emerging diseases. The human telomerase reverse transcriptase (hTERT), a telomerase catalytic subunit in cancers, has been identified with functional and structural similarities to the viral RdRp, making it a potential target to explore drug repositioning of current anticancer drugs for antiviral usage.</p> Summary <p>Taken together, the investigation of hTERT and other anticancer drugs is essential to explore other uses of existing drugs for COVID-19, especially&#xa0;in such an urgent time of need. This review highlights the prospects of repositioning anticancer drugs against COVID-19 and its limitations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unravelling the Potential of Anticancer Drugs for SARS-CoV-2

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月23日

查看全文
  • Zheng Yao Low,
  • Ka Heng Wong,
  • Ashley Jia Wen Yip,
  • Hern Liang Liew,
  • Isra Ahmad Farouk,
  • Sunil Kumar Lal,
  • Wee Sim Choo

摘要

Purpose of Review

Concerning the COVID-19 pandemic, repositioning several anticancer drugs has modulated SARS-CoV-2-induced inflammatory responses and disrupted viral replication. This review aims to discuss the potential of anticancer drug repositioning (DR) for anti-SARS-CoV-2 RdRp, its limitations, and other notable successes of DR against COVID-19.

Recent Findings

The emergence of SARS-CoV-2, an etiological agent that accounted for the current chaotic COVID-19 episode, has brought many lives away. Notably, the viral RNA-dependent RNA polymerase (RdRp) has contributed significantly to the viral replication of all RNA viruses, including SARS-CoV-2, making it a promising target for drug treatment. The lack of efficacious drugs combined with the prolonged duration of the drug discovery process has prompted many to opt for drug repositioning (DR) as an alternative route to combat current or emerging diseases. The human telomerase reverse transcriptase (hTERT), a telomerase catalytic subunit in cancers, has been identified with functional and structural similarities to the viral RdRp, making it a potential target to explore drug repositioning of current anticancer drugs for antiviral usage.

Summary

Taken together, the investigation of hTERT and other anticancer drugs is essential to explore other uses of existing drugs for COVID-19, especially in such an urgent time of need. This review highlights the prospects of repositioning anticancer drugs against COVID-19 and its limitations.